These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16458793)

  • 21. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
    Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
    Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct patterns of endothelin axis expression in primary prostate cancer.
    Godara G; Pecher S; Jukic DM; D'Antonio JM; Akhavan A; Nelson JB; Pflug BR
    Urology; 2007 Jul; 70(1):209-15. PubMed ID: 17656249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
    Schwartz GG
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.
    Riley GF; Warren JL; Potosky AL; Klabunde CN; Harlan LC; Osswald MB
    Med Care; 2008 Oct; 46(10):1108-15. PubMed ID: 18815533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethnogenetic layering (EL): an alternative to the traditional race model in human variation and health disparity studies.
    Jackson FL
    Ann Hum Biol; 2008; 35(2):121-44. PubMed ID: 18428008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of human papillomavirus infections in prostate cancer progression.
    Al Moustafa AE
    Med Hypotheses; 2008 Aug; 71(2):209-11. PubMed ID: 18468811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The critical use of population-based medical databases for prostate cancer research.
    Scales CD; Dahm P
    Curr Opin Urol; 2008 May; 18(3):320-5. PubMed ID: 18382243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogens and mechanisms of prostate cancer progression.
    Carruba G
    Ann N Y Acad Sci; 2006 Nov; 1089():201-17. PubMed ID: 17261768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer prevention: past, present, and future.
    Fleshner N; Zlotta AR
    Cancer; 2007 Nov; 110(9):1889-99. PubMed ID: 17893870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
    Shariat SF; Lamb DJ; Iyengar RG; Roehrborn CG; Slawin KM
    Clin Cancer Res; 2008 Jan; 14(2):607-11. PubMed ID: 18223237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    Coard KC; Skeete DH
    BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer: genes, environment, immunity and the use of immunotherapy.
    Karan D; Thrasher JB; Lubaroff D
    Prostate Cancer Prostatic Dis; 2008; 11(3):230-6. PubMed ID: 18283297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States.
    Colli JL; Amling CL
    Urol Oncol; 2009; 27(2):170-3. PubMed ID: 18367120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.